MONMOUTH JUNCTION, N.J., June 6, 2017 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a
critical care immunotherapy leader using CytoSorb® blood
purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces that it has
joined forces with investor relations firm, LifeSci Advisors, LLC to anchor its outreach to the broader investment community.
"We are delighted to be engaged with CytoSorbents to help create a comprehensive and impactful investor relations program,"
said Michael Rice, founder of LifeSci Partners. "The company has been successful in getting its
CytoSorb blood purification technology onto the market in Europe, sales are on a positive growth
trajectory, and there is a clear path to FDA approval in the U.S. As with all LifeSci Partners clients, we see this
relationship as a partnership, and we look forward to collaborating with Dr. Phillip Chan and his
team to raise the company's profile and attract new institutional and retail investors."
Dr. Phillip Chan, CEO of CytoSorbents stated, "We have been greatly impressed with the robust
infrastructure and extensive network of healthcare investors, analysts, bankers, and other key resources that LifeSci Advisors
brings to bear for its clients. LifeSci has an outstanding track record of recruiting excellent people with strong ties to
Wall Street, and excels in organizing non-deal roadshows, research, corporate communications, key opinion leader events, broker
meetings, and other activities that help companies such as ours rise above the noise. As a company commercializing our
CytoSorb blood purification technology in 43 countries worldwide, we believe we can leverage their capabilities, particularly
their physical international presence in major financial hubs such as London, Switzerland, and Israel, to rapidly spread our message to investors in the
U.S. and around the globe. We are excited to move ahead with Michael and his team."
About CytoSorbents Corporation (NASDAQ: CTSO )
CytoSorbents Corporation is a leader in
critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 43 countries
around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine
release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as
sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the
risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery
to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications,
including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center,
randomized controlled study that has demonstrated the safety and efficacy of free hemoglobin reduction with intra-operative
CytoSorb® use in a heart-lung machine during complex cardiac surgery. In 2017, the company plans to initiate a pivotal
REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb® has been used safely in more than 23,000 human treatments
to date.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic
substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding in excess of $19 million from DARPA, the U.S. Army, the U.S. Department of Health
and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special
Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood
purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL,
HemoDefend™, VetResQ™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at
www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by
the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified
by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential,"
"continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the
forward-looking statements in this press release represent management's current judgment and expectations, but our actual
results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed
with the SEC on March 3, 2017, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press
releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of
the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Cytosorbents Contact:
Amy Vogel
Investor Relations
(732) 398-5394
avogel@cytosorbents.com
Investor Relations Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com
Public Relations Contact:
Amy Phillips
Pascale Communications
412-327-9499
amy@pascalecommunications.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytosorbents---a-leader-in-blood-purification-to-treat-deadly-inflammation---teams-with-investor-relations-firm-lifesci-advisors-300469432.html
SOURCE CytoSorbents Corporation